Tharimmune, Inc.
Sireesh Appajosyula is an experienced professional in the biotechnology and pharmaceutical industries, currently serving as Chief Operating Officer at Tharimmune, Inc. since July 2023. As Managing Partner at Channel BioConsulting, LLC. since 2015, Sireesh has demonstrated leadership in corporate development and operations, previously holding the position of SVP at 9 Meters Biopharma, Inc. until June 2023. Sireesh co-founded HighPoint Therapeutics, Inc. and has held various roles at Salix Pharmaceuticals, Amgen, Critical Therapeutics, and sanofi-aventis, showcasing expertise in marketing, medical affairs, and scientific communication. Sireesh holds a Doctor of Pharmacy (PharmD) degree from Rutgers University, earned between 1994 and 2000.
This person is not in the org chart
This person is not in any teams
Tharimmune, Inc.
Tharimmune, Inc. (Nasdaq: THAR) is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset, known to suppress chronic, debilitating pruritis or "uncontrollable itching" in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting unique epitopes with novel mechanisms of action against well-known, validated targets in multiple solid tumors. Tharimmune has a license agreement with OmniAb, Inc. to access the company's antibody discovery technology platform against specified targets. For more information please visit: www.tharimmune.com